Combination methods of treating cancer
OwnerNicholas Bacopoulos, Judy Chiao +5inventors
InventorsNicholas Bacopoulos, Judy Chiao, Paul Marks, Thomas Miller, Carolyn Paradise, Victoria Richon, Richard Rifkind
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof, in a first treatment procedure, and a second amount of an anti-cancer agent in a second treatment procedure. The first and second amounts together comprise a therapeutically effective amount. The effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.
Claims24
A method of treating cancer in a subject in need thereof, comprising administering to the subject a first amount of suberoylanilide hydroxamic acid (SAHA) represented by the structure:
- or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of an anti-cancer agent, thereby treating the cancer.
-14. (canceled)
-32. (canceled)
-49. (canceled)
-105. (canceled)
A method of selectively inducing terminal differentiation of neoplastic cells in a subject and thereby inhibiting proliferation of said cells in said subject, said method comprising administering to said subject a first amount of suberoylanilide hydroxamic acid (SAHA) represented by the structure:
- or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of an anti-cancer agent, thereby inducing terminal differentiation of said cells.
-108. (canceled)
An in-vitro method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of said cells, said method comprising contacting the cells with a first amount of suberoylanilide hydroxamic acid (SAHA) represented by the structure:
- or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of an anti-cancer agent, thereby inducing terminal differentiation of said cells.
-111. (canceled)
A pharmaceutical composition comprising a first amount of suberoylanilide hydroxamic acid (SAHA) represented by the structure:
- or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of an anti-cancer agent.
Dependencies are inferred from the claim text.